Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

OMEPRAZOLE

All products: Limited Use (codes 293, 297, 401, 402)

Other products in the same Health Canada class (A02BC) — coverage varies; not interchangeable

  • Pantoprazole (Tecta): general benefit
  • Rabeprazole (Pariet): general benefit
  • Lansoprazole (Prevacid): limited Use 293, 295, 297, 401, 402
  • Pantoprazole (Pantoloc): limited Use 293, 295, 297, 401, 402, Not a benefit
  • Dexlansoprazole (Dexilant): not a benefit
  • Esomeprazole (Nexium DR Tab): not a benefit

7 more in the class list below

Apo-Omeprazole Cap · DIN 02245058 · 20mg ·

Limited Use — Reason for Use code 293, 297, 401, 402 requiredMarketed · checked 2026-09-19
StatusLimited Use — Reason for Use code 293, 297, 401, 402 required
Write on scriptLU code 293, 297, 401, 402 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 293, 297, 401, 402
Reason for Use code 293 Gastroesophageal Reflux Disease (GERD) For the treatment of erosive GERD or upper GI malignancy; OR For the treatment of non-erosive GERD after failure of H2-receptor antagonist therapy. Patients with GERD should be reassessed within 6 months after initial treatment with a PPI. The reassessment could include confirmation of need for PPI with endoscopy, a trial of PPI withdrawal, or step-down therapy to H2-receptor antagonist therapy. Note: There is a lack of published evidence to support double-dose PPI therapy in this setting. Coverage limit: LU Authorization Period: 1 year Reason for Use code 297 Confirmed Peptic Ulcers or NSAID-induced Ulcer Prophylaxis: For the treatment of confirmed peptic ulcers and NSAID-induced ulcers; OR For the prophylaxis of NSAID-induced ulcers for patients at increased risk of GI bleeding. Note: There is a lack of published evidence to support double-dose PPI therapy in this setting. Coverage limit: LU Authorization Period: 1 year Reason for Use code 401 Other Gastrointestinal Disorders: For the treatment of gastroduodenal Crohns disease, short-gut syndrome, scleroderma, or pancreatitis. Note: There is a lack of published evidence to support double-dose PPI therapy in these settings. Coverage limit: LU Authorization Period: 1 year Reason for Use code 402 Severe Conditions: For the treatment of severe esophagitis, Zollinger-Ellison syndrome, esophageal stricture, persistent symptoms of GERD or persistent erosive esophagitis, or upon hospital discharge following a gastrointestinal bleed. For patients receiving double-dose therapy, the need to continue treatment at higher doses should be reassessed after eight weeks. For re-treatment at higher doses, a four-week period should have elapsed from the end of the previous treatment. Reassessment could include a procedural assessment of the condition or step-down therapy to lower-dose proton pump inhibitor (PPI) therapy. Coverage limit: LU Authorization Period: 1 year
1 brand, same coverage
Apo-Omeprazole Cap · DIN 02245058 Manufacturer: Apotex Inc.; listing date 2004-07-20 Health Canada: Marketed since 2004-01-28 · brand APO-OMEPRAZOLE · ATC A02BC01 OMEPRAZOLE · form Capsule (delayed-release) · route Oral · ingredients OMEPRAZOLE 20 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Omeprazole Cap: Formulary list price $0.2287/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2287 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=69062 · Verify on the e-Formulary ↗ (DIN 02245058)

Source record
DIN 02245058: Apo-Omeprazole Cap Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y Item: 564000070; group id 689; item number 1710; lccId 00168; manufacturer id APX Source form: None; strength: 20mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2287; ministry $0.2287 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02245058 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=69062
Interchangeable products
Jamp-Omeprazole DR Tab · DIN 02420198 · $0.2287 Losec DR Tab · DIN 02190915 · not recorded Omeprazole Magnesium Delayed Release Tab · DIN 02416549 · $0.2287 Omeprazole Magnesium Delayed Release Tab · DIN 02504294 · $0.2287 Omeprazole-20 DR Cap · DIN 02411857 · $0.2287 PMS-Omeprazole DR Cap · DIN 09857342 · $0.2287 Ratio-Omeprazole DR Tab · DIN 02260867 · $0.2287 Sandoz Omeprazole DR Cap · DIN 02296446 · $0.2287 Teva-Omeprazole DR Tab · DIN 02295415 · $0.2287
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (56:40 Miscellaneous G.I. Drugs) and how they are covered

Matched class: 56:40 Miscellaneous G.I. Drugs

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: BUDESONIDE, MESALAZINE, NIZATIDINE, OLSALAZINE SODIUM, PANTOPRAZOLE MAGNESIUM, RABEPRAZOLE SODIUM, SUCRALFATE Some products covered without a code (check the product listing): 5-AMINOSALICYLIC ACID, CIMETIDINE, DOMPERIDONE MALEATE, FAMOTIDINE, LACTULOSE, METOCLOPRAMIDE HCL, MISOPROSTOL, RANITIDINE HCL 56:40 Miscellaneous G.I. Drugs

PANTOPRAZOLE MAGNESIUM

· 6 products · General benefit · strengths: 40mg · Ent Coated Tab

RABEPRAZOLE SODIUM

· 16 products · General benefit · strengths: 10mg, 20mg · Tab

LANSOPRAZOLE

· 16 products · Limited Use, codes 293, 295, 297, 401, 402 · strengths: 15mg, 30mg · DR Cap

PANTOPRAZOLE SODIUM

· 30 products · Off-Formulary Interchangeable, not an ODB benefit (10), Limited Use, codes 293, 295, 297, 401, 402 (20) · strengths: 20mg, 40mg · Ent Tab

DEXLANSOPRAZOLE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 30mg, 60mg · DR Cap

ESOMEPRAZOLE

· 22 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 40mg, 20mg · DR Tab

CIMETIDINE

· 10 products · General benefit (5), Listed, not a benefit (5) · strengths: 200mg, 300mg, 400mg, 600mg, 800mg · Tab

FAMOTIDINE

· 16 products · Listed, not a benefit (2), General benefit (14) · strengths: 20mg, 40mg · Tab

MISOPROSTOL

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 100mcg, 200mcg · Tab

NIZATIDINE

· 2 products · General benefit · strengths: 150mg, 300mg · Cap

RANITIDINE HCL

· 23 products · Listed, not a benefit (3), General benefit (20) · strengths: 15mg/mL, 150mg, 300mg · Oral Sol, Tab

SUCRALFATE

· 4 products · General benefit · strengths: 1g/5mL, 1g · Oral Susp, Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 56:40 and 10 more
Full class listing Related classes: 56:04 Antacids and Adsorbents, 56:08 Antidiarrhea Agents, 56:12 Cathartics, 56:16 Digestants, 56:22 Antiemetics and Antinauseants Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS LOSEC (omeprazole) is indicated in the treatment of conditions where a reduction of gastric acid secretion is required, such as: • duodenal ulcer; • gastric ulcer; • NSAID-associated gastric and duodenal ulcers; • reflux esophagitis; • symptomatic gastroesophageal reflux disease (GERD), i.e., heartburn and regurgitation; • Zollinger-Ellison syndrome (pathological hypersecretory condition); • eradication of Helicobacter pylori (H. pylori). LOSEC, in combination with clarithromycin and either amoxicillin or metronidazole, is indicated for the treatment of patients with peptic ulcer disease associated with Helicobacter pylori infection. The optimal timing for eradication therapy in patients whose ulcer is not clinically active (i.e., asymptomatic) remains to be determined. 1.1 Pediatrics No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics Evidence from clinical studies and experience suggests that use in the geriatric population is associated with differences in safety or effectiveness. https://pdf.hres.ca/dpd_pm/00072924.PDF PM date: JAN 13, 1989 Source product: LOSEC; DIN 00846503; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.